Search Results - "Varbanova, V"

Family-based Association Study of Killer Cell Immunoglobulin-Like Receptor Genes with Leukemia by Varbanova, V., Mihaylova, S., Naumova, E., Cotoc, C., Mihaylova, A.

“…NK cell function is controlled by the cell expression of killer immunoglobulin-like receptors (KIRs) and their ligation with the corresponding HLA ligands…”
Get full text

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data) by Varbanova V., Anastasova-Postadzhiyan A., Nedeva A., Nikolov I., Kindekov I., Kuyumdzhieva Y., Petkova N., Vikentieva E., Lubomir M., Raynov J.

“…Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies…”
Get full text

Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report by Mihaylov, G, Varbanova, V, Stoeva, V, Dikov, T

“…Chronic myelogenous leukemia (CML) is a hematological malignancy that originates in an abnormal pluripotent bone marrow stem cell. CML is consistently…”
Get full text

Quantitative research on health determinants in high-income countries: Systematic literature review by Varbanova, V, Beutels, P

“…Abstract Background Identifying determinants of health and understanding their role in health production is an important research theme. In recent decades data…”
Get full text

PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA by Djambazov, S., Slavchev, G., Encheva-Malinova, M., Pavlova, Y., Varbanova, V., Velchev, M., Vekov, T.

Get full text

PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA by Djambazov, S., Slavchev, G., Encheva-Malinova, M., Varbanova, V., Velchev, M., Raduilov, B., Vekov, T.

Get full text

PB2095 OUTCOME AFTER AZACITITINE TREATMENT IN PATIENTS WITH HIGH‐RISK MYEOLODYSPLASTIC SYNDROME, CHRONIC MYELOMONOCYTIC LEUKEMIA TYPE 2 AND ACUTE MYELOID LEUKEMIA–A SINGLE CENTER EXPERIENCE by Varbanova, V., Nicolov, I., Nedeva, A., Petkova, N., Kindekov, I., Kuyumdzhieva, Y., Anastasova‐Postadzhiyan, M., Kuncheva, T., Vikentieva, E., Popova, D., Mitev, L., Raynov, J.

“…Background: Hypomethylating agents have become a standard therapy for intermediate‐2 and high‐risk International Prognostic Scoring System (IPSS)…”
Get full text

Particular KIRs and KIR/HLA profiles may influence the susceptibility to all by Varbanova, V, Avramova, B, Yordanova, M, Mihaylova, A, Naumova, E

Get full text

Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report by Mihaylov, G, Varbanova, V, Stoeva, V, Dikov, T

“…BACKGROUNDChronic myelogenous leukemia (CML) is a hematological malignancy that originates in an abnormal pluripotent bone marrow stem cell. CML is…”
Get full text